Table 1.
Clinical and pathological characteristics of p.R337H and non-p.R337H carriers.
| Cohort characteristics | Total cohort n = 87 (%) | p.R337H n = 72 (%) | Non-p.R337H n = 15 (%) | p-value |
|---|---|---|---|---|
| Age of BC diagnosis | ||||
| <31 yr | 10 (11.5) | 6 (8.3) | 4 (26.7) | |
| 31–45 yr | 58 (66.7) | 49 (68.1) | 9 (60) | |
| >45 yr | 19 (21.8) | 17 (26.3) | 2 (13.3) | |
| Median age | 38 | 39.5 | 34 | 0.009 |
| Revised Chompret criteria | 40 (46) | 31 (43.1) | 9 (60) | 0.231 |
| Bilateral BC | 12 | 8 | 4 | 0.209 |
| Synchronous | 4 (33.3) | 2 (25) | 2 (50) | |
| Metachronous | 8 (66.6) | 6 (75) | 2 (50) | |
| Histology | 0.015 | |||
| IBC | 69 (72) | 60 (77.9) | 9 (47.4) | |
| DCIS | 25 (26) | 15 (19.5) | 10 (52.6) | |
| STS | 2 (2) | 2 (2.6) | 0 | |
| HR status | 0.365 | |||
| HR+ | 74 (89.2) | 61 (91) | 13 (81.2) | |
| HR− | 9 (10.8) | 6 (9) | 3 (18.8) | |
| HER2 status | 0.621 | |||
| HER2+ | 32 (41) | 25 (39.7) | 7 (46.7) | |
| HER2− | 46 (59) | 38 (60.3) | 8 (53.3) | |
| HR/HER2 co-expression | 0.219 | |||
| HR+/HER2+ | 27 (34.6) | 23 (36.5) | 4 (26.7) | |
| HR+/HER2− | 43 (55.1) | 35 (55.6) | 8 (53.3) | |
| HR−/HER2+ | 6 (7.7) | 3 (4.8) | 3 (20) | |
| HR−/HER2− | 2 (2.6) | 2 (3.2) | 0 |
BC, Breast cancer; yr, Years; IBC, Invasive breast carcinoma; DCIS, Ductal carcinoma in situ; STS, Soft tissue sarcoma; IHC, Immunohistochemistry; HR, Hormone receptor; HER2, Human epidermal growth factor receptor 2.